Viva Biotech Holdings

SEHK:1873 Stock Report

Market Cap: HK$1.9b

Viva Biotech Holdings Management

Management criteria checks 4/4

Viva Biotech Holdings' CEO is Chen Cheney Mao, appointed in Jul 2018, has a tenure of 6.58 years. total yearly compensation is CN¥2.39M, comprised of 60.8% salary and 39.2% bonuses, including company stock and options. directly owns 15.88% of the company’s shares, worth HK$295.12M. The average tenure of the management team and the board of directors is 3.9 years and 5.8 years respectively.

Key information

Chen Cheney Mao

Chief executive officer

CN¥2.4m

Total compensation

CEO salary percentage60.8%
CEO tenure6.6yrs
CEO ownership15.9%
Management average tenure3.9yrs
Board average tenure5.8yrs

Recent management updates

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19
Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Recent updates

Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

Oct 14
Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Aug 30
Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19
Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03
Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26
A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19
Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11
Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Dec 23
Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Nov 06
Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Jun 13
Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Apr 17
We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13
Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06
Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02
What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21
Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

CEO Compensation Analysis

How has Chen Cheney Mao's remuneration changed compared to Viva Biotech Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥318k

Mar 31 2024n/an/a

-CN¥58m

Dec 31 2023CN¥2mCN¥1m

-CN¥116m

Sep 30 2023n/an/a

-CN¥276m

Jun 30 2023n/an/a

-CN¥436m

Mar 31 2023n/an/a

-CN¥482m

Dec 31 2022CN¥3mCN¥1m

-CN¥528m

Sep 30 2022n/an/a

-CN¥209m

Jun 30 2022n/an/a

CN¥111m

Mar 31 2022n/an/a

CN¥199m

Dec 31 2021CN¥2mCN¥1m

CN¥288m

Sep 30 2021n/an/a

CN¥258m

Jun 30 2021n/an/a

CN¥228m

Mar 31 2021n/an/a

-CN¥79m

Dec 31 2020CN¥1mCN¥957k

-CN¥387m

Sep 30 2020n/an/a

-CN¥349m

Jun 30 2020n/an/a

-CN¥311m

Mar 31 2020n/an/a

-CN¥23m

Dec 31 2019CN¥1mCN¥954k

CN¥266m

Compensation vs Market: Chen Cheney's total compensation ($USD328.50K) is about average for companies of similar size in the Hong Kong market ($USD332.51K).

Compensation vs Earnings: Chen Cheney's compensation has been consistent with company performance over the past year.

CEO

Chen Cheney Mao (62 yo)

6.6yrs

Tenure

CN¥2,394,000

Compensation

Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...

Leadership Team

NamePositionTenureCompensationOwnership
Chen Cheney Mao
Chairman & CEO6.6yrsCN¥2.39m15.88%
HK$ 295.1m
Ying Wu
Executive VP & Executive Director6.6yrsCN¥2.68m0.82%
HK$ 15.2m
Delin Ren
Executive Director1.2yrsCN¥3.68m0.70%
HK$ 13.0m
Wei Xiong
Chief Financial Officerless than a yearno datano data
Xueheng Cheng
Chief Technology Officer5.5yrsno datano data
Zhixiong Ye
Chief Scientific Officer6.6yrsno datano data
Han Dai
Chief Innovation Officer & Head of Viva BioInnovatorno datano datano data
Jianhua Cai
Senior Vice Presidentno datano datano data
Jianguo Ma
Senior VP & President of Shanghai Langhua Pharmaceuticalno datano datano data
Xianyong Bu
CBO & EVP of Viva Biotech (Shanghai)no datano datano data
Rongqiang Liu
Senior Vice President2.3yrsno datano data
Derek Ren
CEO of Viva Biotech (Shanghai) Ltd.1.1yrsno datano data

3.9yrs

Average Tenure

61.5yo

Average Age

Experienced Management: 1873's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chen Cheney Mao
Chairman & CEO6.6yrsCN¥2.39m15.88%
HK$ 295.1m
Ying Wu
Executive VP & Executive Director15.4yrsCN¥2.68m0.82%
HK$ 15.2m
Delin Ren
Executive Director6.6yrsCN¥3.68m0.70%
HK$ 13.0m
Haiguang Wang
Independent Non-Executive Director5.8yrsCN¥225.00kno data
Lei Fu
Independent Non-Executive Director5.8yrsCN¥225.00kno data
Xiangrong Li
Independent Non-Executive Director5.8yrsCN¥225.00kno data
Yuting Wu
Non-Executive Director2.3yrsCN¥225.00kno data
Hui Wang
Non-Executive Director1.1yrsno data4.02%
HK$ 74.8m

5.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 1873's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 11:09
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viva Biotech Holdings is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Dennis IpDaiwa Securities Co. Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.